Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
US-12173314-B2 · Dec 24, 2024 · US
US9265801B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9265801-B2 |
| Application number | US-201514667405-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 24, 2015 |
| Priority date | Aug 17, 2006 |
| Publication date | Feb 23, 2016 |
| Grant date | Feb 23, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.
Opening claim text (preview).
What is claimed is: 1. A packaged sterile dehydrated placental tissue graft having a front side and a back side, wherein the placental tissue graft has at least one label, design, mark, or other configuration on a portion thereof which visually distinguishes the orientation of the graft and wherein the label, design, mark, or other configuration is formed or configured by the placental tissue. 2. The graft of claim 1 , wherein the at least one label, design, mark, or other configuration is a notch. 3. The graft of claim 1 , wherein the at least one label, design, mark, or other configuration visually distinguishes the front side from the back side of the graft. 4. The graft of claim 1 , wherein the tissue graft comprises amnion. 5. The graft of claim 1 , wherein the tissue graft comprises chorion. 6. The graft of claim 1 , wherein the tissue graft comprises amnion and chorion. 7. The graft of claim 1 , wherein the at least one label, design, mark, or other configuration is an embossment. 8. A packaged sterile dehydrated placental tissue graft having a front side and a back side, wherein the placental tissue graft has at least one label, design, mark, or other configuration on a portion thereof which visually distinguishes the orientation of the graft and wherein the label, design, mark, or other configuration is formed or configured by the placental tissue, and further wherein said tissue graft is a dehydrated, laminated graft containing two or more layers wherein said layers are selected from amnion and chorion provided that at least one of said layers is an amnion layer which retains its fibroblast layer further provided that the layers are laminated to each other. 9. The graft of claim 8 , wherein the fibroblast layer of said amnion layer is laminated to an amnion or chorion layer.
Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title
Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title
characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel · CPC title
Tissue-regenerating or healing or proliferative agents · CPC title
subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.